MindMed to Present at Canaccord Genuity’s 44th Annual Growth Conference
MindMed, a clinical-stage biopharmaceutical company focused on brain health disorders, has announced its participation in Canaccord Genuity's 44th Annual Growth Conference. The company's management team will engage in a fireside chat on Tuesday, August 13, 2024, at 1:30 PM ET in Boston, MA.
This presentation offers investors and interested parties an opportunity to gain insights into MindMed's progress and future plans. The event will be accessible via audio webcast, with replays available on MindMed's Investor Relations website for up to 90 days after the conference. This participation underscores MindMed's commitment to engaging with the investment community and showcasing its developments in the field of brain health therapeutics.
MindMed, un'azienda biofarmaceutica in fase clinica focalizzata sui disturbi della salute mentale, ha annunciato la sua partecipazione al 44° Annual Growth Conference di Canaccord Genuity. Il team di gestione dell'azienda parteciperà a un fireside chat martedì 13 agosto 2024, alle 13:30 ET a Boston, MA.
Questa presentazione offre a investitori e parti interessate l'opportunità di ottenere informazioni sui progressi e sui piani futuri di MindMed. L'evento sarà accessibile tramite audio webcast, con riproduzioni disponibili sul sito web delle relazioni con gli investitori di MindMed per un massimo di 90 giorni dopo la conferenza. Questa partecipazione sottolinea l'impegno di MindMed a interagire con la comunità degli investitori e a mostrare i suoi sviluppi nel campo delle terapie per la salute mentale.
MindMed, una empresa biofarmacéutica en etapa clínica centrada en trastornos de salud cerebral, ha anunciado su participación en la 44ª Conferencia Anual de Crecimiento de Canaccord Genuity. El equipo de gestión de la empresa participará en un fireside chat el martes 13 de agosto de 2024, a la 1:30 PM ET en Boston, MA.
Esta presentación ofrece a los inversores y partes interesadas la oportunidad de conocer los avances y planes futuros de MindMed. El evento será accesible a través de un audio webcast, con repeticiones disponibles en el sitio web de Relaciones con Inversores de MindMed por hasta 90 días después de la conferencia. Esta participación subraya el compromiso de MindMed de interactuar con la comunidad de inversionistas y mostrar sus desarrollos en el campo de las terapias para la salud cerebral.
MindMed, 뇌 건강 질환에 중점을 둔 임상 단계의 바이오 제약 회사,가 Canaccord Genuity의 제44회 연례 성장 컨퍼런스에 참여한다고 발표했습니다. 회사의 경영팀은 2024년 8월 13일 화요일, 오후 1시 30분 ET에 보스턴, MA에서 파이어사이드 챗에 참여할 예정입니다.
이번 발표는 투자자와 이해관계자에게 MindMed의 진행 상황과 향후 계획에 대한 통찰력을 얻을 수 있는 기회를 제공합니다. 이 행사는 오디오 웹 캐스트를 통해 접근 가능하며, 회의 후 최대 90일 동안 MindMed의 투자자 관계 웹사이트에서 재생할 수 있습니다. 이 참여는 투자 커뮤니티와의 소통 및 뇌 건강 치료 분야의 발전을 보여줄 MindMed의 의지를 강조합니다.
MindMed, une entreprise bio-pharmaceutique en phase clinique axée sur les troubles de la santé cérébrale, a annoncé sa participation à la 44e Conférence Annuelle sur la Croissance de Canaccord Genuity. L'équipe de direction de l'entreprise participera à un fireside chat le mardi 13 août 2024, à 13h30 ET à Boston, MA.
Cette présentation offre aux investisseurs et aux parties intéressées l'opportunité de connaître les progrès et les plans futurs de MindMed. L'événement sera accessible par audio webcast, avec des rediffusions disponibles sur le site des relations investisseurs de MindMed pendant 90 jours après la conférence. Cette participation souligne l'engagement de MindMed à dialoguer avec la communauté des investisseurs et à montrer ses développements dans le domaine des thérapies pour la santé cérébrale.
MindMed, ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Gehirngesundheitsstörungen spezialisiert hat, hat seine Teilnahme an der 44. jährlichen Wachstumskonferenz von Canaccord Genuity angekündigt. Das Managementteam des Unternehmens wird an einem Fireside Chat am Dienstag, den 13. August 2024, um 13:30 Uhr ET in Boston, MA teilnehmen.
Diese Präsentation bietet Investoren und Interessierten die Möglichkeit, Einblicke in die Fortschritte und zukünftigen Pläne von MindMed zu erhalten. Die Veranstaltung wird über Audio-Webcast zugänglich sein, mit Wiederholungen, die bis zu 90 Tage nach der Konferenz auf der Website der Investor Relations von MindMed verfügbar sind. Diese Teilnahme unterstreicht das Engagement von MindMed, mit der Investmentgemeinschaft zu interagieren und seine Entwicklungen im Bereich der Gehirngesundheitstherapien zu präsentieren.
- None.
- None.
-
Canaccord Genuity’s 44th Annual Growth Conference
- Format: Fireside Chat
- Date and Time: Tuesday, August 13, 2024 at 1:30 PM ET
-
Location:
Boston, MA - Webcast Link: Canaccord Genuity’s 44th Annual Growth Conference
Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following the event.
About MindMed
MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806945771/en/
For Media: media@mindmed.co
For Investors: ir@mindmed.co
Source: Mind Medicine Inc.
FAQ
When and where is MindMed (MNMD) presenting at Canaccord Genuity's 44th Annual Growth Conference?
What format will MindMed's (MNMD) presentation take at the Canaccord Genuity conference?
How long will the webcast of MindMed's (MNMD) presentation be available for replay?
What is the focus of MindMed (MNMD) as a company?
